Clinical Trial

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-01-05.
Status change: Not Yet Recruiting → Recruiting 2023-01-31
Trial Details
NCT Number NCT05185505
Lead Sponsor The Methodist Hospital Research Institute
Collaborators: Genentech, Inc.
Conditions Hepatocellular Carcinoma, Hepatocellular Cancer
Enrollment 24 participants
Start Date 2023-01-30
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2023-02-01